Results 71 to 80 of about 16,400 (171)

Individualising endpoints in chronic HBV treatment: HBsAg loss and beyond

Journal of Hepatology
There are many new compounds in development for the treatment of chronic hepatitis B (CHB). Although major on-treatment declines in hepatitis B surface antigen (HBsAg) can be achieved with some of these drugs, achieving sustained post-treatment HBsAg loss with undetectable HBV DNA (functional cure) remains challenging, particularly in patients with ...
Milan J. Sonneveld, Harry L.A. Janssen
openaire   +3 more sources

Real‐world use of second‐generation integrase strand transfer inhibitors (INSTI) as switch therapy in the prospective ANRS‐CO3‐AquiVIH‐NA cohort

HIV Medicine, Volume 27, Issue 6, Page 965-978, June 2026.
Abstract Objectives To characterize real‐world treatment switching in France to bictegravir (BIC or B) or dolutegravir (DTG)‐based regimens with a focus on treatment persistence, effectiveness (HIV‐1 RNA ≤50 copies/ml) and particular attention to the prevalence and incidence of comorbidities. Methods People living with HIV from the prospective ANRS‐CO3‐
O. Leleux, A. Peyrouny‐Mazeau, A. Perrier, M. Hessamfar, G. Le Moal, D. Neau, L. Alleman, C. Cazanave, E. Lazaro, P. Duffau, A. Riché, Y. Gérard, G. Barrière, S. Reigadas, M.‐A. Vandenhende, F. Bonnet   +15 more
wiley   +1 more source

HBsAg levels, HBsAg loss, and HBsAg seroconversion over time in the mITT population and mITT patients with available data.

, 2020
HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; mITT, modified intention-to-treat.
Ulrich Alshuth (631963), Jörg Petersen (76825), Heiner Wedemeyer (32361), Tarik Asselah (717526), Markus Cornberg (32357), Georgios Papatheodoridis (8698080), Patrick Marcellin (706289), Georgios Bakalos (2577070), Teerha Piratvisuth (279131), Robert Flisiak (143093), Pietro Lampertico (2838461), Diethelm Messinger (3166401), Seung Woon Paik (8698074), Denis Ouzan (330140), Qing Xie (104232), Loredana Regep (8698083), Graham R. Foster (8698077)   +16 more
core   +1 more source

A Framework for Emergency Department–Integrated Hepatitis C Test‐and‐Treat in the United States

Journal of Viral Hepatitis, Volume 33, Issue 6, June 2026.
ABSTRACT Despite the availability of curative, direct‐acting antiviral therapy, hepatitis C virus elimination remains incomplete. Losses across the care cascade continue to limit impact, from initial diagnosis to sustained virologic response. Fewer than 1/3 of individuals ultimately achieve cure. These gaps reflect a delivery system that does not align
Saeed S. Graham
wiley   +1 more source

HBsAg loss in chronic hepatitis B: pointers to the benefits of curative therapy [PDF]

Hepatology International, 2016
Geoffrey, Dusheiko, Bo, Wang, Ivana, Carey   +2 more
openaire   +2 more sources

Re‐entry of donors deferred for false‐reactive screening tests in Canada: 10 years post implementation

Vox Sanguinis, Volume 121, Issue 6, Page 779-788, June 2026.
Abstract Background and Objectives Canadian Blood Services implemented a re‐entry programme in 2014. Donors deferred because of false‐reactive or indeterminate screening tests can provide a specimen for re‐entry testing 6 months after their initial test, and resume donating if they test negative for all infectious markers.
Chinchin Wang, Steven J. Drews, Mark Bigham, Mindy Goldman, Sheila F. O'Brien   +4 more
wiley   +1 more source

Loss of HBsAg in nucleoside-naive HBeAg(+) chronic hepatitis B patients following treatment with entecavir or lamivudine: evaluation of HBV genotypes

, 2009
BACKGROUND: Spontaneous HBsAg seroclearance has beenestimated to occur at a rate of 0.5 to 1.7% per year. In thephase III study ETV-022, 5.1% of nucleoside-naïve HBeAg(+)chronic hepatitis B (CHB) patients treated with entecavir (ETV)had confirmed HBsAg ...
De Man, RA, Tang, H, Iloeje, U, Lai, CL, Harris, M, Poordad, F, Brett-Smith, H, Gish, RG, Chang, TT, Xu, D   +9 more
core   +1 more source

HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels

, 2014
Achievement of HBsAg loss remains the hallmark of chronic hepatitis B treatment. In order to identify host factors contributing to treatment-induced HBsAg loss, we performed a genome-wide screen of single nucleotide polymorphisms (SNPs) and studied its ...
Jansen, Louis, Erik P.A. van Iperen, Louis Jansen, Stelma, Femke, de Niet, Annikki, Kootstra, Neeltje A., Zwinderman, A. H. Koos, Uri Lopatin, Femke Stelma, Karel A. van Dort, Takkenberg, R. Bart, Lopatin, Uri, Marjan J. Tempelmans Plat-Sinnige, Hendrik W. Reesink, R. Bart Takkenberg, Neeltje A. Kootstra, van Iperen, Erik P. A., Tempelmans Plat-Sinnige, Marjan J., Annikki de Niet, Chin, Daniel J., A.H. (Koos) Zwinderman, Daniel J. Chin, Reesink, Hendrik W., van Dort, Karel A.   +23 more
core   +1 more source

Histologic findings in patients with chronic hepatitis B with HBsAg loss.

, 2002
의학과/석사[한글] B형 간염 바이러스(Hepatitis B virus, HBV)는 우리나라에서 만성 간질환의 가장 중요하고 흔한 원인으로 HBV 만성 감염의 자연 경과는 바이러스의 증식에 따라 그리고, 환자의 면역 상태에 따라 면역관용기, 면역제거기, 비증식기로 구분할 수 있다.
박준용
core  

Immune drivers of HBsAg loss in HBeAg-negative CHB patients after stopping nucleotide analog and administration of Peg-IFN. [PDF]

Hepatol Commun, 2023
Islam M, Kumar K, Sevak JK, Jindal A, Vyas AK, Ramakrishna G, Ramakrishna G, Kottilil S, Sharma MK, Sarin SK, Trehanpati N.   +10 more
europepmc   +1 more source